Research

We have six important clinical trials at Retina Associates of Florida. We are currently enrolling patients in the following studies: WET AMD: LADDER trail, Diabetic Retinopathy - DRCR Protocol U trial, and DRCR Protocol AB trial.

  • DRY AMD: closed to enrollment
    Lampalizumab trial (Genentech/Roche)
    COMPARES: Lampalizumab vs control
    ELIGIBILITY: Patients with areas of geographic atrophy and good visual acuity
    DURATION: 12 months
    QUESTION: Does lampalizumab reduce rate of vision loss and progression? Is there a genetic subtype that has better outcome?
  • WET AMD: currently enrolling
    LADDER (Genentech/Roche)
    COMPARES: Lucentis Port Delivery System Implant (PDS) vs Lucentis monthly
    ELIGIBILITY: Patients will be randomized to 3 doses of PDS or Lucentis
    DURATION: 2 years
    QUESTION: Time until PDS needs refilling in 3 different doses vs Lucentis monthly
  • WET AMD: closed to enrollment
    Darpin Abicipar trial (Allergan)
    COMPARES: Abicipar Q8wk vs Abicipar Q12wk vs Lucentis Q4 wks
    ELIGIBILITY: Patients will be randomized to one of three groups with newly diagnosed wet AMD with vision 20/40 – 20/320.
    DURATION: 2 years
    QUESTION: Is Abicipar dosed at Q8 or Q12 wk noninferior to Lucentis Q4 wk
  • DIABETIC RETINOPATHY: currently enrolling
    DRCR Protocol U trial

    COMPARES: Lucentis (Anti-VEGF) + Dexamethasone (steroid) vs Lucentis alone ELIGIBILITY: Patients will be randomized to combination therapy vs monotherapy for recurrent diabetic macular edema and at least 6 previous injections of Anti-VEGF with vision of 20/30 – 20/300. Patients must have had previous cataract surgery.
    DURATION: 12 months
    QUESTION: Which treatment is best for preserving good visual acuity?
  • DRCR Protocol V trial: closed to enrollment
    COMPARES: Macular Laser + Lucentis vs Prompt Lucentis (Anti-VEGF) vs Observation and deferred Lucentis
    ELIGIBILITY: New diagnosis of diabetic macular with vision of 20/25 or better.
    DURATION: 2 years
    QUESTION: Which treatment is best for preserving good visual acuity?
  • DRCR Protocol AB trial: currently enrolling
    COMPARES: Intravitreal Eylea vs Vitrectomy for Vitreous Hemorrhage from PDR
    ELIGIBILITY: Vision of 20/32 or worse.
    DURATION: 2 years
    QUESTION: Which treatment provides best vision at 24 weeks?

The trials are sponsored, so eligible patients will not incur additional costs. We encourage you to refer eligible patients as they would benefit from the studies and help us answer important questions.

Questions: Contact Janet @ RAF 813.875.6373 ext 239 or email Janet